Isgandar M. A.

THE EFFECT OF BLOOD PRESSURE WITHIN THE RANGE OF «130/80 – 139/89 MM HG» ON THE MAGNITUDE OF CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

---

Show/Download

About the author:

Isgandar M. A.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

The outpatient records of 596 patients in the archives of the Azerbaijan Association of Endocrinology, Diabetology and Therapeutic Training were analyzed. A group with DM2 (n=450) was identified. To determine the effect of the blood pressure level on the value of CVR, the group participants were divided into 3 subgroups: 1) a subgroup of "Ideal Normotension" (n=71), which included people with blood pressure within the normal range according to both ESC/ESH (2018) and ACC/AHA (2017) criteria; 2) a subgroup of "Ideal Hypertension" (n=125), which included people with hypertension according to both ESC/ESH (2018) and ACC/AHA (2017) criteria; 3) a subgroup of "Intermediate BP" (n=254), which included people with hypertension according to ACC/AHA criteria (2017) and "high norm" according to ESC/ESH criteria (2018). To determine the CVR, the following methods were used: PROCAM risk score; Framigham risk score based on lipid profile; Framigham risk score based on body mass index; QRISK 2 risk score; Pooled Cohort Equations risk score; ASCVD risk score. The average values of the CVR level in the "Ideal Normotension" subgroup of the DM2 group were 8.5% (95% CI. 7.80; 9.28). In the "Intermediate BP" subgroup, this indicator corresponded to 12.9% (95% CI.12.32; 13.51), and in the subgroup of "Ideal hypertension" the value of cardiovascular risk was 18.0% (95% CI 17.43; 18.55). The differences between all subgroups were statistically highly significant p<0.001. The use of CVR calculators both individually and in combination in patients in the DM2 group indicate that an increase in SBP to 130-139 mmHg and/or DBP to 80-89 mmHg contributed to an increase in cardiovascular risk. It can be assumed that a further increase in blood pressure further increases this risk.

Tags:

Bibliography:

1. Manolis AJ, Poulimenos LE, Kallistratos MS. Arterial hypertension: benefits and limitations of treatment. e-Journal of Cardiology Practice. 2015;13(28). Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/arterial-hypertensionbenefits-and-limitations-of-treatment.
2. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:13-115.
3. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39:3021-3104.
4. Lewington S, Clarke R, Quizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet. 2002;14(360):1903-1913.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet. 2000 Dec 9;356(9246):1955-64. DOI: 10.1016/s0140-6736(00)03307-9.
6. Kallistratos MS, Poulimenos LE, Manolis AJ. Vasodilator β-blockers: a different class of antihypertensive agents? Future Cardiol. 2014 Nov;10(6):669-71. DOI: 10.2217/fca.14.51.
7. Di Nicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013 Jul;125(4):154-68. DOI: 10.3810/pgm.2013.07.2687.
8. Manolis AJ, Marketou ME, Gavras I, Gavras H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res. 2010 Aug;33(8):772-7. DOI: 10.1038/hr.2010.82.
9. Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):4-15. DOI: 10.2174/15701611113119990140.
10. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44. DOI: 10.1161/ CIR.0b013e31820a55f5.
11. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105(3):310-5. DOI: 10.1161/hc0302.102575.
12. D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117:743-53.
13. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475-82.
14. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2014 Jun 24;129(25(2)):49-73. DOI: 10.1161/01.cir.0000 437741.48606.98.
15. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2014;129:S1–S45. DOI: 10.1161/01. cir.0000437738.63853.7a.
16. Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, et al. Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2017 Mar 28;135(13):e793-e813. DOI: 10.1161/CIR.00000 00000000467.
17. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/ AphA/AS PC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Jun 18;139(25):e1082-e1143. DOI: 10.1161/ CIR.0000000000000625.
18. Microsoft Excel. Excel 2016 – get it now with an Office 365 subscription [Internet]. Available from: https://products.office.com/en-us/excel.
19. EPITOOLS. Calculate confidence limits for a sample proportion [Internet]. Available from: https://epitools.ausvet.com.au/ciproportion.
20. Easy Calculation.com. Confidence Limits for Mean Calculator [Internet]. Available from: https://www.easycalculation.com/statistics/ confidence-limits-mean.php.
21. Peat J, Barton B. Medical Statistics. A Guide to Data Analysis and Critical Appraisal. Blackwell Publishing; 2005. 324 s.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 4, 171, 195-199 pages, index UDC 616.12 – 008.331.1; 616.1; 616.379-008.64

DOI:

10.29254/2077-4214-2023-4-171-195-199